Results 1 to 10 of about 69,866 (217)

The triptan formulations: a critical evaluation Formulações dos triptanos: avaliacão crítica

Arquivos de Neuro-Psiquiatria, 2003
The migraine-specific triptans have revolutionized the treatment of migraine and are usually the drugs of choice to treat a migraine attack in progress.
Marcelo E. Bigal, Carlos A. Bordini, Ana L. Antoniazzi, José G. Speciali   +3 more
doaj   +1 more source

Factors associated with insufficient response to acute treatment of migraine in Japan: analysis of real-world data from the Adelphi Migraine Disease Specific Programme

BMC Neurology, 2020
Background Real-world data on sufficient/insufficient response, and predictors of insufficient response, to acute treatments for migraine are limited in Japan.
Koichi Hirata, Kaname Ueda, Wenyu Ye, Yongin Kim, Mika Komori, James Jackson, Sarah Cotton, Narayan Rajan, Tamas Treuer   +8 more
doaj   +1 more source

Multimodal Migraine Management and the Pursuit of Migraine Freedom: A Narrative Review

Neurology and Therapy, 2023
Migraine is a neurologic disease with a complex pathophysiology that can be controlled with current treatment options but not cured. Therefore, treatment expectations are highly variable.
Andrew M. Blumenfeld, Richard B. Lipton, Stephen Silberstein, Stewart J. Tepper, Larry Charleston, Stephen Landy, Deena E. Kuruvilla, Aubrey Manack Adams   +7 more
doaj   +1 more source

Stopping Onabotulinum Treatment after the First Two Cycles Might Not Be Justified: Results of a Real-life Monocentric Prospective Study in Chronic Migraine

Frontiers in Neurology, 2017
IntroductionOnabotulinum toxin A (OnabotA) cyclic treatment is approved for the prophylactic treatment of chronic migraine (CM), a highly disabling disorder.
Paola Sarchielli, Michele Romoli, Ilenia Corbelli, Laura Bernetti, Angela Verzina, Elona Brahimi, Paolo Eusebi, Stefano Caproni, Paolo Calabresi, Paolo Calabresi   +9 more
doaj   +1 more source

Early antiseizure response to cenobamate (200 mg/day) in focal drug-resistant epilepsy: a retrospective single-center analysis

Epilepsy & Behavior Reports
Clinical studies have shown cenobamate (CNB) is effective for treating drug-resistant focal epilepsy. This study examines Polish patients with epilepsy, assessing the efficacy and safety of CNB at 200 mg/day and factors influencing early therapeutic ...
Ewa Czapińska-Ciepiela, Agnieszka Kondak, Monika Kowalczyk, Piotr Czapiński   +3 more
doaj   +1 more source

Migraine symptoms, healthcare resources utilization and disease burden in a large Polish migraine cohort

The Journal of Headache and Pain, 2023
Background The Migraine in Poland study is the first large scale nationwide cross-sectional online survey of symptoms, approaches to management, treatment patterns, quality of life, and sociodemographic characteristics of the Polish migraine patients ...
Marta Waliszewska-Prosół, Marcin Straburzyński, Ewa K. Czapińska-Ciepiela, Magdalena Nowaczewska, Anna Gryglas-Dworak, Sławomir Budrewicz   +5 more
doaj   +1 more source

How to effectively treat migraine attacks

Медицинский совет, 2014
Migraine is one of the most common causes of disability of young and middle-aged people. Many patients with migraine are not satisfied with drugs used for the treatment.
V. A. Parfyonov
doaj   +3 more sources

EFFICACY AND TOLERABILITY OF STOPAIN FOR A MIGRAINE ATTACK

Frontiers in Neurology, 2015
ObjectiveTo determine whether topical menthol 6% gel will relieve a migraine attack.Materials and MethodsA single-center, open-label pilot trial of 25 patients with at least one year of diagnosed episodic migraine and < 15 headache days per month ...
Andrea eSt. Cyr, Ashley eChen, Kathleen C. Bradley, Hsiangkuo eYuan, Stephen D. Silberstein, William B. Young   +5 more
doaj   +1 more source

Preventive treatment patterns and treatment satisfaction in migraine: results of the OVERCOME (EU) study

The Journal of Headache and Pain, 2023
Background Insights into the burden, needs and treatment of migraine from internet-based surveys in diverse real-world migraine populations are needed, especially at a time when novel preventive migraine medications are becoming part of the therapeutic ...
Julio Pascual, Tommaso Panni, Grazia Dell’Agnello, Saygin Gonderten, Diego Novick, Stefan Evers   +5 more
doaj   +1 more source

Histamine intolerance, DAO deficiency and their impact on health in the context of migraine development and treatment: a review

Journal of Education, Health and Sport
Introduction and purpose  Migraine is a prevalent neurological disorder affecting up to 1 billion individuals worldwide. Histamine intolerance, caused by reduced activity of the diamine oxidase enzyme, has been increasingly linked to migraines, with ...
Agata Białek, Magdalena Mendak, Anna Hanslik, Agnieszka Walczak , Adrian Hovagimyan , Monika Olszanecka, Tomasz Olszanecki   +6 more
doaj   +1 more source